Stabilizing atherosclerotic lesions and preventing plaque ruptures can be seen as the holy grail in vascular medicine. In this issue of Molecular Therapy, Jin et al suggest local delivery of a microRNA-21 (miR-21) mimic as a potential therapeutic strategy to reduce plaque vulnerability. Interestingly, inhibition of this microRNA has also been proposed as a therapeutic approach for in-stent restenosis, where the application of anti-miR-21 oligonucleotides on stents improved vessel patency 1 .
Atherosclerosis is a chronic inflammatory disease resulting from the build-up of lipid deposits in the innermost layer of an artery. Apart from lipids, atherosclerotic plaques comprise mainly smooth muscle cells, macrophages, calcium and fibrous connective tissue. Upon rupture or erosion of vulnerable atherosclerotic plaques, platelet aggregation results in thrombus formation that can occlude the vessel lumen.
Stents are metallic scaffolds placed into the occluded segment of a diseased artery to hold it open. Current drug-eluting stents (DES) are designed to inhibit vascular smooth muscle cell (SMC) proliferation to reduce neo-intima formation within the stent lumen. Whilst greatly enhancing stent patency in coronary arteries, these antiproliferative agents also inhibit the proliferation of endothelial cells, thus delaying reendothelialization and arterial healing. After DES implantation, dual antiplatelet therapy is therefore required to prevent the inherent risk of thrombosis and stent occlusion. Alternatives to current DES that would inhibit SMC proliferation without delaying re-endothelialization should result in less thrombogenicity.
In the vasculature, miR-21 has previously been implicated as a determinant of SMC proliferation [2] [3] [4] [5] . For example, pharmacological and genetic miR-21 inhibition markedly decreased neo-intima formation in vein grafts 4, 5 and balloon-injured carotid arteries 2 . These findings led to the exploration of local therapeutic strategies by coating stents with miR-21 inhibitors. When deployed in denuded arteries in rats, this approach prevented SMC-mediated in-stent restenosis without delaying re-
Conversely, SMC proliferation can also be beneficial in stabilizing the vessel wall and atherosclerotic plaques. For example, the proliferative effects of miR-21 mimics in SMCs reduced the expansion of abdominal aortic aneurysms 6 Finally, local delivery of miR-21 mimics to carotid plaques using ultrasound-targeted microbubble destruction enhanced plaque stability. These findings suggest that by increasing SMC proliferation, miR-21 mimics could stabilize the SMC-rich fibrous cap that shields the lipid-filled core of atherosclerotic plaques.
As is the case for most miRNAs, miR-21 is ubiquitously expressed 7 . It is particularly abundant in circulating hematopoietic cells, where it appears to act as an 'emergency brake' on inflammation. In macrophages, miR-21 directly targets the proinflammatory programmed cell death protein 4 (PDCD4), thereby increasing the secretion of anti-inflammatory interleukin-10 (IL-10) 8 . MiR-21 also directly targets phosphatase and tensin homolog (PTEN), steering macrophages towards a reparative phenotype that promotes resolution of inflammation and tissue recovery 9 .
Thus, miR-21 may also modulate tissue inflammation, in part through monocyte differentiation toward an anti-inflammatory macrophage phenotype. A common challenge in miRNA research is to identify the cell types that are responsible for the observed therapeutic benefits. Although the present study confirms a mechanistic link between miR-21 and SMC proliferation, it remains unclear whether the beneficial effect relies predominantly on SMCs, macrophages or other cell types. Using a multi-omics approach, we recently identified a protein signature of symptomatic atherosclerotic plaques that implied a shared involvement of immune cells and SMCs 11 . Also, the plasticity of SMCs is currently under debate, with lineage tracing experiments suggesting a potential SMC origin of macrophagelike cell types 12, 13 . Finally, apoE mediates the reverse cholesterol transport 14 and atherosclerosis is known to differ between man and apoE null mice 15 . 
